<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8795">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02992457</url>
  </required_header>
  <id_info>
    <org_study_id>Asem Elfert</org_study_id>
    <nct_id>NCT02992457</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Post-hepatitis C Cirrhosis</brief_title>
  <official_title>Retrospective Study of the Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Post-hepatitis C Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Egypt has the highest prevalence of hepatitis C virus (HCV) in the world, estimated
      nationally at 14.7%. Genotype 4 (and subtype 4a in particular) dominates the HCV epidemic in
      Egypt. For decades the antiviral therapy of chronic HCV infection was based on the
      administration of Interferon(IFN), initially alone and then in combination with Ribavirin
      (RBV), but this regimen was effective in only 50% of patients with genotype 1, with
      significant side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Egypt has the highest prevalence of hepatitis C virus (HCV) in the world, estimated
      nationally at 14.7%. Genotype 4 (and subtype 4a in particular) dominates the HCV epidemic in
      Egypt. For decades the antiviral therapy of chronic HCV infection was based on the
      administration ofInterferon(IFN), initially alone and then in combination with Ribavirin
      (RBV), but this regimen was effective in only 50% of patients with genotype 1, with
      significant side effects. The introduction of direct acting antiviral agents, in particular
      sofosbuvir (SOF), has revolutionized the treatment for chronic hepatitis C virus.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with sustained virological response.</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Sof-Riba</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir ribavirin 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sof- Riba- Pegylated interferon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir, Ribavirin and Pegylated-interferon alfa-2a 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sof- Olysio</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir and simeprevir for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sof- Dacla</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir and Daclatasvir for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Sofosbuvir 400 mg daily.</description>
    <arm_group_label>Sof-Riba</arm_group_label>
    <arm_group_label>Sof- Riba- Pegylated interferon</arm_group_label>
    <arm_group_label>Sof- Olysio</arm_group_label>
    <arm_group_label>Sof- Dacla</arm_group_label>
    <other_name>sovaldi , mpiviropack</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin 1000-1200 mg daily</description>
    <arm_group_label>Sof-Riba</arm_group_label>
    <arm_group_label>Sof- Riba- Pegylated interferon</arm_group_label>
    <other_name>Rebetol, Riba</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated-interferon alfa-2a</intervention_name>
    <description>Pegylated interferon alfa-2a once weekly for 3 months</description>
    <arm_group_label>Sof- Riba- Pegylated interferon</arm_group_label>
    <other_name>peginteron, pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir</intervention_name>
    <description>Olysio once daily.</description>
    <arm_group_label>Sof- Olysio</arm_group_label>
    <other_name>Olysio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Dakla once daily for three months.</description>
    <arm_group_label>Sof- Dacla</arm_group_label>
    <other_name>Daklatasvir, Dakla</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • HCV infection

               -  Adult patients, 18years and older.

        Exclusion Criteria:

          -  • Child score &gt; 12

               -  Severe Renal impairment

               -  Pregnant and lactating women

               -  HCC or other malignant neoplasms

               -  Co-infection with human immunodeficiency virus (HIV)

               -  Co-infection with hepatitis B virus (HBV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asem Elfert, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta university hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lobna Abo ALi, Ass Prof</last_name>
    <role>Study Director</role>
    <affiliation>Tanta university hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabry Abou Saif, Ass Prof</last_name>
    <role>Study Director</role>
    <affiliation>Tanta university hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taher Eldemerdash, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Tanta University hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hala M Elsabagh, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Tanta University hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Elkassas, Lecturer</last_name>
    <role>Study Director</role>
    <affiliation>Helwan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eslam Esmail, Ass Lecturer</last_name>
    <role>Study Chair</role>
    <affiliation>Tanta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherief Abd-Elsalam, MD</last_name>
    <phone>00201095159522</phone>
    <email>sheriefabdelsalam@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sherief Abd-Elsalam</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherief Abd-elsalam, lecturer</last_name>
      <phone>00201000040794</phone>
      <email>Sherif_tropical@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tanta university hospital</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abd-Elsalam</last_name>
      <phone>00201000040794</phone>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 10, 2016</lastchanged_date>
  <firstreceived_date>December 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
